世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

ベータラクタムおよびベータラクタマーゼ阻害剤の世界市場に関する洞察、2028年までの予測


Global Beta-lactam and Beta-lactamase Inhibitors Market Insights, Forecast to 2028

市場の分析と洞察。ベータラクタムおよびベータラクタマーゼ阻害剤の世界市場 COVID-19の大流行により、β-ラクタム薬およびβ-ラクタマーゼ阻害剤の世界市場規模は2022年に2億7730万米ドル、2028年には3億1119万... もっと見る

 

 

出版社 出版年月 電子版価格 言語
QYResearch
QYリサーチ
2022年3月31日 US$4,900
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
英語

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


 

サマリー

市場の分析と洞察。ベータラクタムおよびベータラクタマーゼ阻害剤の世界市場
COVID-19の大流行により、β-ラクタム薬およびβ-ラクタマーゼ阻害剤の世界市場規模は2022年に2億7730万米ドル、2028年には3億1119万米ドルに再調整されると予測され、予測期間2022-2028年にはCAGR 1.94% が予測されています。この健康危機による経済変化を十分に考慮すると、2021年にベータラクタムおよびベータラクタマーゼ阻害剤の世界市場の26.96%を占めるセファロスポリンは、2028年までに8344百万米ドルの価値を持つと予測されます。

世界のβ-ラクタムおよびβ-ラクタマーゼ阻害剤の範囲とセグメント
ベータラクタムおよびベータラクタマーゼ阻害剤市場は、タイプ別および用途別に分類されます。世界のβ-ラクタムおよびβ-ラクタマーゼ阻害剤市場におけるプレイヤー、ステークホルダー、その他の参加者は、本レポートを強力なリソースとして利用することで、優位に立つことができるようになることでしょう。セグメント別分析では、2017年から2028年までのタイプ別、アプリケーション別の売上、収益、予測に焦点を当てます。

会社別
ファイザー
ノバルティス(サンド)
TEVA
メルク
AbbVie(アラガン)
大日本住友製薬
ヒグマ
オーロビンド・ファーマ
ウォックハート
ルパン・リミテッド
フレゼニウス・カビ
B. ブラウン
ユサンチビオティック
斉魯薬業
ACSドブファル
日医工(サジェント)
アンチオティック

種類別セグメント
ペニシリン系
セファロスポリン
カルバペネム系抗生物質
モノバクタム系
組合せ

用途別セグメント
経口
静脈内注射

地域別セグメント
北アメリカ
米国
カナダ
アジア太平洋地域
中国
日本
韓国
インド
オーストラリア
フィリピン
インドネシア
タイ
マレーシア
ヨーロッパ
ドイツ
フランス
英国
イタリア
ロシア
ラテンアメリカ
メキシコ
ブラジル
アルゼンチン
中東・アフリカ
トルコ
サウジアラビア
UAE

ページTOPに戻る


目次


1 STUDY COVERAGE 1
1.1 Beta-lactam and Beta-lactamase Inhibitors Product Introduction 1
1.2 Market by Type 2
1.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 2
1.2.2 Penicillins 3
1.2.3 Cephalosporins 6
1.2.4 Carbapenems 8
1.2.5 Monobactams 10
1.3 Market by Application 12
1.3.1 Global Beta-lactam and Beta-lactamase Inhibitors Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 12
1.3.2 Oral 13
1.3.3 Intravenous 13
1.4 Study Objectives 14
1.5 Years Considered 15
2 EXECUTIVE SUMMARY 16
2.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales Estimates and Forecasts 2017-2028 16
2.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue Estimates and Forecasts 2017-2028 17
2.3 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Region: 2017 VS 2021 VS 2028 18
2.4 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Region 19
2.4.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Region (2017-2022) 19
2.4.2 Global Sales Beta-lactam and Beta-lactamase Inhibitors by Region (2023-2028) 21
2.5 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Region 22
2.5.1 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Region (2017-2022) 22
2.5.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Region (2023-2028) 23
2.6 North America 24
2.7 Europe 25
2.8 Asia-Pacific 26
2.9 Latin America 28
2.10 Middle East & Africa 29
3 COMPETITION BY MANUFACTURERS 31
3.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Manufacturers 31
3.1.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Manufacturers (2017-2022) 31
3.1.2 Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Manufacturers (2017-2022) 32
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Beta-lactam and Beta-lactamase Inhibitors in 2021 33
3.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Manufacturers 34
3.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Manufacturers (2017-2022) 34
3.2.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Manufacturers (2017-2022) 35
3.2.3 Global Top 10 and Top 5 Companies by Beta-lactam and Beta-lactamase Inhibitors Revenue in 2021 36
3.3 Global Beta-lactam and Beta-lactamase Inhibitors Sales Price by Manufacturers (2017-2022) 38
3.4 Analysis of Competitive Landscape 38
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI) 38
3.4.2 Global Beta-lactam and Beta-lactamase Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 39
3.4.3 Global Beta-lactam and Beta-lactamase Inhibitors Manufacturers Geographical Distribution 41
3.5 Mergers & Acquisitions, Expansion Plans 43
4 MARKET SIZE BY TYPE 46
4.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Type 46
4.1.1 Global Beta-lactam and Beta-lactamase Inhibitors Historical Sales by Type (2017-2022) 46
4.1.2 Global Beta-lactam and Beta-lactamase Inhibitors Forecasted Sales by Type (2023-2028) 46
4.1.3 Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Type (2017-2028) 47
4.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Type 48
4.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Historical Revenue by Type (2017-2022) 48
4.2.2 Global Beta-lactam and Beta-lactamase Inhibitors Forecasted Revenue by Type (2023-2028) 49
4.2.3 Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Type (2017-2028) 49
4.3 Global Beta-lactam and Beta-lactamase Inhibitors Price by Type 50
4.3.1 Global Beta-lactam and Beta-lactamase Inhibitors Price by Type (2017-2022) 50
4.3.2 Global Beta-lactam and Beta-lactamase Inhibitors Price Forecast by Type (2023-2028) 51
5 MARKET SIZE BY APPLICATION 52
5.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Application 52
5.1.1 Global Beta-lactam and Beta-lactamase Inhibitors Historical Sales by Application (2017-2022) 52
5.1.2 Global Beta-lactam and Beta-lactamase Inhibitors Forecasted Sales by Application (2023-2028) 52
5.1.3 Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Application (2017-2028) 53
5.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Application 54
5.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Historical Revenue by Application (2017-2022) 54
5.2.2 Global Beta-lactam and Beta-lactamase Inhibitors Forecasted Revenue by Application (2023-2028) 54
5.2.3 Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Application (2017-2028) 54
5.3 Global Beta-lactam and Beta-lactamase Inhibitors Price by Application 56
5.3.1 Global Beta-lactam and Beta-lactamase Inhibitors Price by Application (2017-2022) 56
5.3.2 Global Beta-lactam and Beta-lactamase Inhibitors Price Forecast by Application (2023-2028) 56
6 NORTH AMERICA 57
6.1 North America Beta-lactam and Beta-lactamase Inhibitors Market Size by Type 57
6.1.1 North America Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2017-2028) 57
6.1.2 North America Beta-lactam and Beta-lactamase Inhibitors Revenue by Type (2017-2028) 58
6.2 North America Beta-lactam and Beta-lactamase Inhibitors Market Size by Application 59
6.2.1 North America Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2017-2028) 59
6.2.2 North America Beta-lactam and Beta-lactamase Inhibitors Revenue by Application (2017-2028) 60
6.3 North America Beta-lactam and Beta-lactamase Inhibitors Sales by Country 62
6.3.1 North America Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2017-2028) 62
6.3.2 North America Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2017-2028) 63
6.3.3 United States 64
6.3.4 Canada 65
7 EUROPE 66
7.1 Europe Beta-lactam and Beta-lactamase Inhibitors Market Size by Type 66
7.1.1 Europe Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2017-2028) 66
7.1.2 Europe Beta-lactam and Beta-lactamase Inhibitors Revenue by Type (2017-2028) 67
7.2 Europe Beta-lactam and Beta-lactamase Inhibitors Market Size by Application 68
7.2.1 Europe Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2017-2028) 68
7.2.2 Europe Beta-lactam and Beta-lactamase Inhibitors Revenue by Application (2017-2028) 69
7.3 Europe Beta-lactam and Beta-lactamase Inhibitors Market Size by Country 71
7.3.1 Europe Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2017-2028) 71
7.3.2 Europe Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2017-2028) 72
7.3.3 Germany 74
7.3.4 U.K. 74
7.3.5 France 75
7.3.6 Italy 76
7.3.7 Russia 76
8 ASIA PACIFIC 78
8.1 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Size by Type 78
8.1.1 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2017-2028) 78
8.1.2 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Revenue by Type (2017-2028) 79
8.2 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Size by Application 80
8.2.1 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2017-2028) 80
8.2.2 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Revenue by Application (2017-2028) 81
8.3 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Size by Region 83
8.3.1 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Sales by Region (2017-2028) 83
8.3.2 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Revenue by Region (2017-2028) 85
8.3.3 China 87
8.3.4 Japan 87
8.3.5 South Korea 88
8.3.6 India 89
8.3.7 Australia 89
8.3.8 Indonesia 90
8.3.9 Thailand 91
8.3.10 Malaysia 92
8.3.11 Philippines 93
9 LATIN AMERICA 94
9.1 Latin America Beta-lactam and Beta-lactamase Inhibitors Market Size by Type 94
9.1.1 Latin America Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2017-2028) 94
9.1.2 Latin America Beta-lactam and Beta-lactamase Inhibitors Revenue by Type (2017-2028) 95
9.2 Latin America Beta-lactam and Beta-lactamase Inhibitors Market Size by Application 96
9.2.1 Latin America Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2017-2028) 96
9.2.2 Latin America Beta-lactam and Beta-lactamase Inhibitors Revenue by Application (2017-2028) 97
9.3 Latin America Beta-lactam and Beta-lactamase Inhibitors Market Size by Country 99
9.3.1 Latin America Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2017-2028) 99
9.3.2 Latin America Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2017-2028) 100
9.3.3 Mexico 102
9.3.4 Brazil 102
9.3.5 Argentina 103
10 MIDDLE EAST AND AFRICA 104
10.1 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Market Size by Type 104
10.1.1 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2017-2028) 104
10.1.2 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Revenue by Type (2017-2028) 105
10.2 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Market Size by Application 106
10.2.1 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2017-2028) 106
10.2.2 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Revenue by Application (2017-2028) 107
10.3 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Market Size by Country 109
10.3.1 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2017-2028) 109
10.3.2 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2017-2028) 110
10.3.3 Turkey 112
10.3.4 Saudi Arabia 112
10.3.5 UAE 113
11 COMPANY PROFILES 114
11.1 Pfizer 114
11.1.1 Pfizer Corporation Information 114
11.1.2 Pfizer Description and Business Overview 114
11.1.3 Pfizer Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 115
11.1.4 Pfizer Beta-lactam and Beta-lactamase Inhibitors Products Offered 115
11.2 Novartis (Sandoz) 119
11.2.1 Novartis (Sandoz) Corporation Information 119
11.2.2 Novartis (Sandoz) Description and Business Overview 119
11.2.3 Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 120
11.2.4 Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Products Offered 120
11.3 TEVA 124
11.3.1 TEVA Corporation Information 124
11.3.2 TEVA Description and Business Overview 124
11.3.3 TEVA Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 125
11.3.4 TEVA Beta-lactam and Beta-lactamase Inhibitors Products Offered 125
11.4 Merck 127
11.4.1 Merck Corporation Information 127
11.4.2 Merck Description and Business Overview 127
11.4.3 Merck Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 128
11.4.4 Merck Beta-lactam and Beta-lactamase Inhibitors Products Offered 128
11.5 AbbVie (Allergan) 128
11.5.1 AbbVie (Allergan) Corporation Information 128
11.5.2 AbbVie (Allergan) Description and Business Overview 129
11.5.3 AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 129
11.5.4 AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Products Offered 130
11.6 Sumitomo Dainippon 130
11.6.1 Sumitomo Dainippon Corporation Information 130
11.6.2 Sumitomo Dainippon Description and Business Overview 131
11.6.3 Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 131
11.6.4 Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Products Offered 132
11.7 Hikma 132
11.7.1 Hikma Corporation Information 132
11.7.2 Hikma Description and Business Overview 132
11.7.3 Hikma Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 133
11.7.4 Hikma Beta-lactam and Beta-lactamase Inhibitors Products Offered 133
11.8 Aurobindo Pharma 135
11.8.1 Aurobindo Pharma Corporation Information 135
11.8.2 Aurobindo Pharma Description and Business Overview 135
11.8.3 Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 135
11.8.4 Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Products Offered 136
11.9 Wockhardt 136
11.9.1 Wockhardt Corporation Information 136
11.9.2 Wockhardt Description and Business Overview 137
11.9.3 Wockhardt Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 137
11.9.4 Wockhardt Beta-lactam and Beta-lactamase Inhibitors Products Offered 137
11.10 Lupin Limited 138
11.10.1 Lupin Limited Corporation Information 138
11.10.2 Lupin Limited Description and Business Overview 138
11.10.3 Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 138
11.10.4 Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Products Offered 139
11.11 Fresenius Kabi 141
11.11.1 Fresenius Kabi Corporation Information 141
11.11.2 Fresenius Kabi Description and Business Overview 142
11.11.3 Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 142
11.11.4 Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Products Offered 143
11.12 B. Braun 143
11.12.1 B. Braun Corporation Information 143
11.12.2 B. Braun Description and Business Overview 144
11.12.3 B. Braun Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 144
11.12.4 B. Braun Beta-lactam and Beta-lactamase Inhibitors Products Offered 144
11.13 USantibiotics 145
11.13.1 USantibiotics Corporation Information 145
11.13.2 USantibiotics Description and Business Overview 146
11.13.3 USantibiotics Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 146
11.13.4 USantibiotics Beta-lactam and Beta-lactamase Inhibitors Products Offered 146
11.14 Qilu Pharmaceutical 147
11.14.1 Qilu Pharmaceutical Corporation Information 147
11.14.2 Qilu Pharmaceutical Description and Business Overview 147
11.14.3 Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 148
11.14.4 Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Products Offered 148
11.15 ACS Dobfar 149
11.15.1 ACS Dobfar Corporation Information 149
11.15.2 ACS Dobfar Description and Business Overview 149
11.15.3 ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 149
11.15.4 ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Products Offered 150
11.16 Nichi-Iko (Sagent) 151
11.16.1 Nichi-Iko (Sagent) Corporation Information 151
11.16.2 Nichi-Iko (Sagent) Description and Business Overview 152
11.16.3 Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 152
11.16.4 Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Products Offered 153
11.17 Antibiotice 156
11.17.1 Antibiotice Corporation Information 156
11.17.2 Antibiotice Description and Business Overview 156
11.17.3 Antibiotice Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 157
11.17.4 Antibiotice Beta-lactam and Beta-lactamase Inhibitors Products Offered 157
12 MARKET DRIVERS, OPPORTUNITIES, CHALLENGES FACTORS ANALYSIS 159
12.1 Beta-lactam and Beta-lactamase Inhibitors Industry Trends 159
12.2 Beta-lactam and Beta-lactamase Inhibitors Market Drivers 159
12.3 Beta-lactam and Beta-lactamase Inhibitors Market Challenges 160
13 VALUE CHAIN AND SALES CHANNELS ANALYSIS 161
13.1 Value Chain Analysis 161
13.2 Beta-lactam and Beta-lactamase Inhibitors Customers 161
13.3 Sales Channels Analysis 162
13.3.1 Sales Channels 162
13.3.2 Distributors 163
14 RESEARCH FINDINGS AND CONCLUSION 166
15 APPENDIX 167
15.1 Research Methodology 167
15.1.1 Methodology/Research Approach 167
15.1.2 Data Source 170
15.2 Author Details 172
15.3 Disclaimer 173

 

ページTOPに戻る


 

Summary

Market Analysis and Insights: Global Beta-lactam and Beta-lactamase Inhibitors Market
Due to the COVID-19 pandemic, the global Beta-lactam and Beta-lactamase Inhibitors market size is estimated to be worth US$ 27730 million in 2022 and is forecast to a readjusted size of US$ 31119 million by 2028 with a CAGR of 1.94% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, Cephalosporins accounting for 26.96% of the Beta-lactam and Beta-lactamase Inhibitors global market in 2021, is projected to value US$ 8344 million by 2028.

Global Beta-lactam and Beta-lactamase Inhibitors Scope and Segment
Beta-lactam and Beta-lactamase Inhibitors market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Beta-lactam and Beta-lactamase Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type, and by Application for the period 2017-2028.

By Company
Pfizer
Novartis (Sandoz)
TEVA
Merck
AbbVie (Allergan)
Sumitomo Dainippon
Hikma
Aurobindo Pharma
Wockhardt
Lupin Limited
Fresenius Kabi
B. Braun
USantibiotics
Qilu Pharmaceutical
ACS Dobfar
Nichi-Iko (Sagent)
Antibiotice

Segment by Type
Penicillins
Cephalosporins
Carbapenems
Monobactams
Combinations

Segment by Application
Oral
Intravenous

Segment by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
Philippines
Indonesia
Thailand
Malaysia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE



ページTOPに戻る


Table of Contents


1 STUDY COVERAGE 1
1.1 Beta-lactam and Beta-lactamase Inhibitors Product Introduction 1
1.2 Market by Type 2
1.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 2
1.2.2 Penicillins 3
1.2.3 Cephalosporins 6
1.2.4 Carbapenems 8
1.2.5 Monobactams 10
1.3 Market by Application 12
1.3.1 Global Beta-lactam and Beta-lactamase Inhibitors Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 12
1.3.2 Oral 13
1.3.3 Intravenous 13
1.4 Study Objectives 14
1.5 Years Considered 15
2 EXECUTIVE SUMMARY 16
2.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales Estimates and Forecasts 2017-2028 16
2.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue Estimates and Forecasts 2017-2028 17
2.3 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Region: 2017 VS 2021 VS 2028 18
2.4 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Region 19
2.4.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Region (2017-2022) 19
2.4.2 Global Sales Beta-lactam and Beta-lactamase Inhibitors by Region (2023-2028) 21
2.5 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Region 22
2.5.1 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Region (2017-2022) 22
2.5.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Region (2023-2028) 23
2.6 North America 24
2.7 Europe 25
2.8 Asia-Pacific 26
2.9 Latin America 28
2.10 Middle East & Africa 29
3 COMPETITION BY MANUFACTURERS 31
3.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Manufacturers 31
3.1.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Manufacturers (2017-2022) 31
3.1.2 Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Manufacturers (2017-2022) 32
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Beta-lactam and Beta-lactamase Inhibitors in 2021 33
3.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Manufacturers 34
3.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Manufacturers (2017-2022) 34
3.2.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Manufacturers (2017-2022) 35
3.2.3 Global Top 10 and Top 5 Companies by Beta-lactam and Beta-lactamase Inhibitors Revenue in 2021 36
3.3 Global Beta-lactam and Beta-lactamase Inhibitors Sales Price by Manufacturers (2017-2022) 38
3.4 Analysis of Competitive Landscape 38
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI) 38
3.4.2 Global Beta-lactam and Beta-lactamase Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 39
3.4.3 Global Beta-lactam and Beta-lactamase Inhibitors Manufacturers Geographical Distribution 41
3.5 Mergers & Acquisitions, Expansion Plans 43
4 MARKET SIZE BY TYPE 46
4.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Type 46
4.1.1 Global Beta-lactam and Beta-lactamase Inhibitors Historical Sales by Type (2017-2022) 46
4.1.2 Global Beta-lactam and Beta-lactamase Inhibitors Forecasted Sales by Type (2023-2028) 46
4.1.3 Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Type (2017-2028) 47
4.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Type 48
4.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Historical Revenue by Type (2017-2022) 48
4.2.2 Global Beta-lactam and Beta-lactamase Inhibitors Forecasted Revenue by Type (2023-2028) 49
4.2.3 Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Type (2017-2028) 49
4.3 Global Beta-lactam and Beta-lactamase Inhibitors Price by Type 50
4.3.1 Global Beta-lactam and Beta-lactamase Inhibitors Price by Type (2017-2022) 50
4.3.2 Global Beta-lactam and Beta-lactamase Inhibitors Price Forecast by Type (2023-2028) 51
5 MARKET SIZE BY APPLICATION 52
5.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Application 52
5.1.1 Global Beta-lactam and Beta-lactamase Inhibitors Historical Sales by Application (2017-2022) 52
5.1.2 Global Beta-lactam and Beta-lactamase Inhibitors Forecasted Sales by Application (2023-2028) 52
5.1.3 Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Application (2017-2028) 53
5.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Application 54
5.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Historical Revenue by Application (2017-2022) 54
5.2.2 Global Beta-lactam and Beta-lactamase Inhibitors Forecasted Revenue by Application (2023-2028) 54
5.2.3 Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Application (2017-2028) 54
5.3 Global Beta-lactam and Beta-lactamase Inhibitors Price by Application 56
5.3.1 Global Beta-lactam and Beta-lactamase Inhibitors Price by Application (2017-2022) 56
5.3.2 Global Beta-lactam and Beta-lactamase Inhibitors Price Forecast by Application (2023-2028) 56
6 NORTH AMERICA 57
6.1 North America Beta-lactam and Beta-lactamase Inhibitors Market Size by Type 57
6.1.1 North America Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2017-2028) 57
6.1.2 North America Beta-lactam and Beta-lactamase Inhibitors Revenue by Type (2017-2028) 58
6.2 North America Beta-lactam and Beta-lactamase Inhibitors Market Size by Application 59
6.2.1 North America Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2017-2028) 59
6.2.2 North America Beta-lactam and Beta-lactamase Inhibitors Revenue by Application (2017-2028) 60
6.3 North America Beta-lactam and Beta-lactamase Inhibitors Sales by Country 62
6.3.1 North America Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2017-2028) 62
6.3.2 North America Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2017-2028) 63
6.3.3 United States 64
6.3.4 Canada 65
7 EUROPE 66
7.1 Europe Beta-lactam and Beta-lactamase Inhibitors Market Size by Type 66
7.1.1 Europe Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2017-2028) 66
7.1.2 Europe Beta-lactam and Beta-lactamase Inhibitors Revenue by Type (2017-2028) 67
7.2 Europe Beta-lactam and Beta-lactamase Inhibitors Market Size by Application 68
7.2.1 Europe Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2017-2028) 68
7.2.2 Europe Beta-lactam and Beta-lactamase Inhibitors Revenue by Application (2017-2028) 69
7.3 Europe Beta-lactam and Beta-lactamase Inhibitors Market Size by Country 71
7.3.1 Europe Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2017-2028) 71
7.3.2 Europe Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2017-2028) 72
7.3.3 Germany 74
7.3.4 U.K. 74
7.3.5 France 75
7.3.6 Italy 76
7.3.7 Russia 76
8 ASIA PACIFIC 78
8.1 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Size by Type 78
8.1.1 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2017-2028) 78
8.1.2 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Revenue by Type (2017-2028) 79
8.2 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Size by Application 80
8.2.1 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2017-2028) 80
8.2.2 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Revenue by Application (2017-2028) 81
8.3 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Size by Region 83
8.3.1 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Sales by Region (2017-2028) 83
8.3.2 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Revenue by Region (2017-2028) 85
8.3.3 China 87
8.3.4 Japan 87
8.3.5 South Korea 88
8.3.6 India 89
8.3.7 Australia 89
8.3.8 Indonesia 90
8.3.9 Thailand 91
8.3.10 Malaysia 92
8.3.11 Philippines 93
9 LATIN AMERICA 94
9.1 Latin America Beta-lactam and Beta-lactamase Inhibitors Market Size by Type 94
9.1.1 Latin America Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2017-2028) 94
9.1.2 Latin America Beta-lactam and Beta-lactamase Inhibitors Revenue by Type (2017-2028) 95
9.2 Latin America Beta-lactam and Beta-lactamase Inhibitors Market Size by Application 96
9.2.1 Latin America Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2017-2028) 96
9.2.2 Latin America Beta-lactam and Beta-lactamase Inhibitors Revenue by Application (2017-2028) 97
9.3 Latin America Beta-lactam and Beta-lactamase Inhibitors Market Size by Country 99
9.3.1 Latin America Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2017-2028) 99
9.3.2 Latin America Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2017-2028) 100
9.3.3 Mexico 102
9.3.4 Brazil 102
9.3.5 Argentina 103
10 MIDDLE EAST AND AFRICA 104
10.1 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Market Size by Type 104
10.1.1 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2017-2028) 104
10.1.2 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Revenue by Type (2017-2028) 105
10.2 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Market Size by Application 106
10.2.1 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2017-2028) 106
10.2.2 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Revenue by Application (2017-2028) 107
10.3 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Market Size by Country 109
10.3.1 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2017-2028) 109
10.3.2 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2017-2028) 110
10.3.3 Turkey 112
10.3.4 Saudi Arabia 112
10.3.5 UAE 113
11 COMPANY PROFILES 114
11.1 Pfizer 114
11.1.1 Pfizer Corporation Information 114
11.1.2 Pfizer Description and Business Overview 114
11.1.3 Pfizer Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 115
11.1.4 Pfizer Beta-lactam and Beta-lactamase Inhibitors Products Offered 115
11.2 Novartis (Sandoz) 119
11.2.1 Novartis (Sandoz) Corporation Information 119
11.2.2 Novartis (Sandoz) Description and Business Overview 119
11.2.3 Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 120
11.2.4 Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Products Offered 120
11.3 TEVA 124
11.3.1 TEVA Corporation Information 124
11.3.2 TEVA Description and Business Overview 124
11.3.3 TEVA Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 125
11.3.4 TEVA Beta-lactam and Beta-lactamase Inhibitors Products Offered 125
11.4 Merck 127
11.4.1 Merck Corporation Information 127
11.4.2 Merck Description and Business Overview 127
11.4.3 Merck Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 128
11.4.4 Merck Beta-lactam and Beta-lactamase Inhibitors Products Offered 128
11.5 AbbVie (Allergan) 128
11.5.1 AbbVie (Allergan) Corporation Information 128
11.5.2 AbbVie (Allergan) Description and Business Overview 129
11.5.3 AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 129
11.5.4 AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Products Offered 130
11.6 Sumitomo Dainippon 130
11.6.1 Sumitomo Dainippon Corporation Information 130
11.6.2 Sumitomo Dainippon Description and Business Overview 131
11.6.3 Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 131
11.6.4 Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Products Offered 132
11.7 Hikma 132
11.7.1 Hikma Corporation Information 132
11.7.2 Hikma Description and Business Overview 132
11.7.3 Hikma Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 133
11.7.4 Hikma Beta-lactam and Beta-lactamase Inhibitors Products Offered 133
11.8 Aurobindo Pharma 135
11.8.1 Aurobindo Pharma Corporation Information 135
11.8.2 Aurobindo Pharma Description and Business Overview 135
11.8.3 Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 135
11.8.4 Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Products Offered 136
11.9 Wockhardt 136
11.9.1 Wockhardt Corporation Information 136
11.9.2 Wockhardt Description and Business Overview 137
11.9.3 Wockhardt Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 137
11.9.4 Wockhardt Beta-lactam and Beta-lactamase Inhibitors Products Offered 137
11.10 Lupin Limited 138
11.10.1 Lupin Limited Corporation Information 138
11.10.2 Lupin Limited Description and Business Overview 138
11.10.3 Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 138
11.10.4 Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Products Offered 139
11.11 Fresenius Kabi 141
11.11.1 Fresenius Kabi Corporation Information 141
11.11.2 Fresenius Kabi Description and Business Overview 142
11.11.3 Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 142
11.11.4 Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Products Offered 143
11.12 B. Braun 143
11.12.1 B. Braun Corporation Information 143
11.12.2 B. Braun Description and Business Overview 144
11.12.3 B. Braun Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 144
11.12.4 B. Braun Beta-lactam and Beta-lactamase Inhibitors Products Offered 144
11.13 USantibiotics 145
11.13.1 USantibiotics Corporation Information 145
11.13.2 USantibiotics Description and Business Overview 146
11.13.3 USantibiotics Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 146
11.13.4 USantibiotics Beta-lactam and Beta-lactamase Inhibitors Products Offered 146
11.14 Qilu Pharmaceutical 147
11.14.1 Qilu Pharmaceutical Corporation Information 147
11.14.2 Qilu Pharmaceutical Description and Business Overview 147
11.14.3 Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 148
11.14.4 Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Products Offered 148
11.15 ACS Dobfar 149
11.15.1 ACS Dobfar Corporation Information 149
11.15.2 ACS Dobfar Description and Business Overview 149
11.15.3 ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 149
11.15.4 ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Products Offered 150
11.16 Nichi-Iko (Sagent) 151
11.16.1 Nichi-Iko (Sagent) Corporation Information 151
11.16.2 Nichi-Iko (Sagent) Description and Business Overview 152
11.16.3 Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 152
11.16.4 Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Products Offered 153
11.17 Antibiotice 156
11.17.1 Antibiotice Corporation Information 156
11.17.2 Antibiotice Description and Business Overview 156
11.17.3 Antibiotice Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 157
11.17.4 Antibiotice Beta-lactam and Beta-lactamase Inhibitors Products Offered 157
12 MARKET DRIVERS, OPPORTUNITIES, CHALLENGES FACTORS ANALYSIS 159
12.1 Beta-lactam and Beta-lactamase Inhibitors Industry Trends 159
12.2 Beta-lactam and Beta-lactamase Inhibitors Market Drivers 159
12.3 Beta-lactam and Beta-lactamase Inhibitors Market Challenges 160
13 VALUE CHAIN AND SALES CHANNELS ANALYSIS 161
13.1 Value Chain Analysis 161
13.2 Beta-lactam and Beta-lactamase Inhibitors Customers 161
13.3 Sales Channels Analysis 162
13.3.1 Sales Channels 162
13.3.2 Distributors 163
14 RESEARCH FINDINGS AND CONCLUSION 166
15 APPENDIX 167
15.1 Research Methodology 167
15.1.1 Methodology/Research Approach 167
15.1.2 Data Source 170
15.2 Author Details 172
15.3 Disclaimer 173

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(抗生物薬)の最新刊レポート


よくあるご質問


QYResearch社はどのような調査会社ですか?


QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。   QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/14 10:27

156.77 円

166.04 円

201.95 円

ページTOPに戻る